Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration SAN DIEGO, Nov. 16, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received European Commission (EC) approval of VYVGART® SC…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks